<p>T-cells from 71 children and young adults with B-cell malignancies on trial to receive anti-CD19 CAR T-cell therapy were analyzed. These T-cells represent the pre-manufacture T-cells that were subsequently used for CAR T manufacture. Bulk RNA-Seq was performed on sorted T-cell subsets for all patients, in addition to CITE-Seq and single-cell ATAC-Seq on a subset of 6 patients. The primary clinical outcome was duration of B-cell aplasia, a surrogate measure of functional CAR T-cell persistence. From these data, molecular signatures associated with long and short-term CAR T-cell persistence were identified. This data submission includes bulk RNA-Seq, CITE-Seq, and single-cell ATAC-Seq data from this study.</p>

Defining and Overcoming Intrinsic T Cell Dysfunction to Enable Pediatric    Immunotherapy

Immunotherapy study with ATAC-seq, RNA-Seq + 4 more data on dbGaP (84 participants)

Defining and Overcoming Intrinsic T Cell Dysfunction to Enable Pediatric Immunotherapy

Description

Applying For Access

Summary